Urokinase Market Increasing prevalence of pulmonary embolism is driving growth of Market 2028 | Jiangsu Aidea Pharmaceutical Co Ltd, Jiangxi Haoran Bio-Pharma Co. Ltd, Cadila Healthcare Limited, Wilex AG.

Increasing prevalence of pulmonary embolism is driving growth of Urokinase market

Market Overview:

Urokinase is a type of thrombolytic drug used to dissolves unwanted blood clots in the lungs.

Competitive Landscape:

Jiangsu Aidea Pharmaceutical Co Ltd, Jiangxi Haoran Bio-Pharma Co., Ltd, Cadila Healthcare Limited, TAJ Pharmaceuticals Limited, Microbix Biosystems Inc, Syner Medica LTD, ImaRx Therapeutics, Inc, and Wilex AG.

Key Market Drivers:

High prevalence of pulmonary embolism is a key factor fostering urokinase market growth. According to National Library of Health in 2018, pulmonary embolism have high prevalence globally with 10 million cases per year.

𝐆𝐞𝐭 𝐅𝐮𝐥𝐥 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭: (𝐈𝐧𝐜𝐥𝐮𝐝𝐢𝐧𝐠 𝐅𝐮𝐥𝐥 𝐓𝐎𝐂, 𝐋𝐢𝐬𝐭 𝐨𝐟 𝐓𝐚𝐛𝐥𝐞𝐬 & 𝐅𝐢𝐠𝐮𝐫𝐞𝐬, 𝐂𝐡𝐚𝐫𝐭) @ https://www.coherentmarketinsights.com/insight/request-pdf/4151

Increasing usage of urokinase drug for heart related disease treatment is again augmenting growth of the market. For example, in June 2020, Hospital of Zhenghou University started clinical trial on the treatment of minor heart stroke with urokinase thrombolysis, which is expected to complete in 2021.

Covid-19 Impact Analysis 

During Covid-19 pandemic the market of urokinase drug witness strong growth due to increasing cases of pulmonary embolism in patients suffering from Covid-19 infection. According to American society of Hematology July 2020, 15-20% of patients suffering from acute pulmonary embolism and deep vein thrombosis require mechanical ventilation and blood clot busting agents after getting infected by COVID-19 infection. Additionally, According to World Health Organization 2019,  it is observed that COVID-19 infection leads to formation of blood clots in patients, thus there is need of blood clot busting agents, when mechanical ventilators are in shortage due to increase in patient population infected by COVID-19 infection.

𝐅𝐨𝐫 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐨𝐫 𝐐𝐮𝐞𝐫𝐲 𝐨𝐫 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐛𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠, 𝐕𝐢𝐬𝐢𝐭 𝐚𝐭 – https://www.coherentmarketinsights.com/insight/talk-to-analyst/4151

Key Takeaways:

1. The urokinase market is expected to exhibit a CAGR of 7.1% over the forecast period owing to the advancement in the treatment process.
2. North America is expected to gain significant growth over the forecast period owing to the increasing prevalence of pulmonary embolism in the region. According to the Centers for Disease Control and Prevention, 60,000-100,000 Americans die of DVT/PE (also called venous thromboembolism). 10 to 30% of people will die within one month of diagnosis. Sudden death is the first symptom in about one-quarter (25%) of people who have a PE.